183 related articles for article (PubMed ID: 31745126)
1. Exploring anticancer activity of structurally modified benzylphenoxyacetamide (BPA); I: Synthesis strategies and computational analyses of substituted BPA variants with high anti-glioblastoma potential.
Stalinska J; Houser L; Rak M; Colley SB; Reiss K; Jursic BS
Sci Rep; 2019 Nov; 9(1):17021. PubMed ID: 31745126
[TBL] [Abstract][Full Text] [Related]
2. Computational modeling and synthesis of pyridine variants of benzoyl-phenoxy-acetamide with high glioblastoma cytotoxicity and brain tumor penetration.
Ingraham CH; Stalinska J; Carson SC; Colley SB; Rak M; Lassak A; Peruzzi F; Reiss K; Jursic BS
Sci Rep; 2023 Jul; 13(1):12236. PubMed ID: 37507404
[TBL] [Abstract][Full Text] [Related]
3. Anti-glioblastoma effects of phenolic variants of benzoylphenoxyacetamide (BPA) with high potential for blood brain barrier penetration.
Stalinska J; Vittori C; Ingraham Iv CH; Carson SC; Plaisance-Bonstaff K; Lassak A; Faia C; Colley SB; Peruzzi F; Reiss K; Jursic BS
Sci Rep; 2022 Mar; 12(1):3384. PubMed ID: 35232976
[TBL] [Abstract][Full Text] [Related]
4. Computational modeling and synthesis of Pyridine variants of Benzoyl-Phenoxy-Acetamide with high glioblastoma cytotoxicity and brain tumor penetration.
Ingraham Iv C; Stalinska J; Carson S; Colley S; Rak M; Lassak A; Reiss K; Jursic B
Res Sq; 2023 Apr; ():. PubMed ID: 37131829
[TBL] [Abstract][Full Text] [Related]
5. Anticancer potential of aminomethylidene-diazinanes I. Synthesis of arylaminomethylidene of diazinetriones and its cytotoxic effects tested in glioblastoma cells.
Pianovich NA; Dean M; Lassak A; Reiss K; Jursic BS
Bioorg Med Chem; 2017 Oct; 25(19):5068-5076. PubMed ID: 28864149
[TBL] [Abstract][Full Text] [Related]
6. Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma.
Skaga E; Kulesskiy E; Fayzullin A; Sandberg CJ; Potdar S; Kyttälä A; Langmoen IA; Laakso A; Gaál-Paavola E; Perola M; Wennerberg K; Vik-Mo EO
BMC Cancer; 2019 Jun; 19(1):628. PubMed ID: 31238897
[TBL] [Abstract][Full Text] [Related]
7. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
8. Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model.
Vignaroli G; Iovenitti G; Zamperini C; Coniglio F; Calandro P; Molinari A; Fallacara AL; Sartucci A; Calgani A; Colecchia D; Mancini A; Festuccia C; Dreassi E; Valoti M; Musumeci F; Chiariello M; Angelucci A; Botta M; Schenone S
J Med Chem; 2017 Jul; 60(14):6305-6320. PubMed ID: 28650650
[TBL] [Abstract][Full Text] [Related]
9. Perphenazine and prochlorperazine induce concentration-dependent loss in human glioblastoma cells viability.
Otręba M; Buszman E
Pharmazie; 2018 Jan; 73(1):19-21. PubMed ID: 29441946
[TBL] [Abstract][Full Text] [Related]
10. Memantine-derived drugs as potential antitumor agents for the treatment of glioblastoma.
Cacciatore I; Fornasari E; Marinelli L; Eusepi P; Ciulla M; Ozdemir O; Tatar A; Turkez H; Di Stefano A
Eur J Pharm Sci; 2017 Nov; 109():402-411. PubMed ID: 28860082
[TBL] [Abstract][Full Text] [Related]
11. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.
Grinshtein N; Rioseco CC; Marcellus R; Uehling D; Aman A; Lun X; Muto O; Podmore L; Lever J; Shen Y; Blough MD; Cairncross GJ; Robbins SM; Jones SJ; Marra MA; Al-Awar R; Senger DL; Kaplan DR
Oncotarget; 2016 Sep; 7(37):59360-59376. PubMed ID: 27449082
[TBL] [Abstract][Full Text] [Related]
12. Improving glioblastoma therapeutic outcomes via doxorubicin-loaded nanomicelles modified with borneol.
Meng L; Chu X; Xing H; Liu X; Xin X; Chen L; Jin M; Guan Y; Huang W; Gao Z
Int J Pharm; 2019 Aug; 567():118485. PubMed ID: 31260781
[TBL] [Abstract][Full Text] [Related]
13. Computational modeling in glioblastoma: from the prediction of blood-brain barrier permeability to the simulation of tumor behavior.
Miranda A; Cova T; Sousa J; Vitorino C; Pais A
Future Med Chem; 2018 Jan; 10(1):121-131. PubMed ID: 29235374
[TBL] [Abstract][Full Text] [Related]
14. Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.
Rundle-Thiele D; Head R; Cosgrove L; Martin JH
Br J Clin Pharmacol; 2016 Feb; 81(2):199-209. PubMed ID: 26374633
[TBL] [Abstract][Full Text] [Related]
15. KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma.
Ciesielski MJ; Bu Y; Munich SA; Teegarden P; Smolinski MP; Clements JL; Lau JYN; Hangauer DG; Fenstermaker RA
J Neurooncol; 2018 Dec; 140(3):519-527. PubMed ID: 30238350
[TBL] [Abstract][Full Text] [Related]
16. Decane-1,2-diol derivatives as potential antitumor agents for the treatment of glioblastoma.
Viswanathan A; Zhurina A; Assoah B; Paakkunainen A; Musa A; Kute D; Saravanan KM; Yli-Harja O; Candeias NR; Kandhavelu M
Eur J Pharmacol; 2018 Oct; 837():105-116. PubMed ID: 30179612
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Preliminary Studies of Spiro-isoxazoline-peroxides against Human Cytomegalovirus and Glioblastoma ∥.
Das P; Hasan MH; Mitra D; Bollavarapu R; Valente EJ; Tandon R; Raucher D; Hamme AT
J Org Chem; 2019 Jun; 84(11):6992-7006. PubMed ID: 31066280
[TBL] [Abstract][Full Text] [Related]
18. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
[TBL] [Abstract][Full Text] [Related]
19. Deglucohellebrin: A Potent Agent for Glioblastoma Treatment.
Vartholomatos E; Alexiou GA; Markopoulos GS; Lazari D; Tsiftsoglou O; Chousidis I; Leonardos I; Kyritsis AP
Anticancer Agents Med Chem; 2020; 20(1):103-110. PubMed ID: 31755397
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship refinement and further assessment of 4-phenylquinazoline-2-carboxamide translocator protein ligands as antiproliferative agents in human glioblastoma tumors.
Castellano S; Taliani S; Viviano M; Milite C; Da Pozzo E; Costa B; Barresi E; Bruno A; Cosconati S; Marinelli L; Greco G; Novellino E; Sbardella G; Da Settimo F; Martini C
J Med Chem; 2014 Mar; 57(6):2413-28. PubMed ID: 24580635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
